# AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

> **NCT00303862** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** cediranib maleate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00303862
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303862, "AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00303862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*